{"disease":{"id":"borderline-resectable-pancreatic-adenocarcinoma","name":"borderline resectable pancreatic adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05083247","title":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":256,"lead_sponsor_name":"Erasme University Hospital","has_results":false},{"nct_id":"NCT04423731","title":"Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT07080021","title":"A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":119,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04481204","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04005690","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06595160","title":"Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05688215","title":"Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07269626","title":"PULSAR in Systemic Therapy for Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07415525","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07240766","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06423326","title":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04915417","title":"Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03970252","title":"Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02394535","title":"Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04484909","title":"NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04106856","title":"Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT06821997","title":"NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT04669197","title":"Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"HonorHealth Research Institute","has_results":false},{"nct_id":"NCT04940286","title":"Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05546411","title":"A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Kimberly Perez, MD","has_results":true}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}